No Data
No Data
Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure
Tharimmune | 10-K: Annual report
Tharimmune Announce Preclinical TH023 Results
12 Health Care Stocks Moving In Monday's Pre-Market Session
Express News | Tharimmune: Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-Alpha
Tharimmune Announces Expansion of Product Pipeline With HS1940